H. Keipp Talbot
A5061113403- Influenza Virus Research Studies
- Respiratory viral infections research
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- Pneumonia and Respiratory Infections
- COVID-19 epidemiological studies
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 detection and testing
- COVID-19 and healthcare impacts
- Long-Term Effects of COVID-19
- COVID-19 Impact on Reproduction
- COVID-19 and Mental Health
- Animal Disease Management and Epidemiology
- Emergency and Acute Care Studies
- Kawasaki Disease and Coronary Complications
- Respiratory Support and Mechanisms
- Data-Driven Disease Surveillance
- Viral Infections and Immunology Research
- Immune Cell Function and Interaction
- Diabetes and associated disorders
- Infectious Encephalopathies and Encephalitis
- Immune Response and Inflammation
- Infection Control and Ventilation
- Bacterial Infections and Vaccines
Vanderbilt University Medical Center
2016-2025
Vanderbilt University
2015-2025
Office of the Assistant Secretary for Health
2024
AID Atlanta
2020-2023
Baylor Scott & White Health
2022-2023
National Center for Emerging and Zoonotic Infectious Diseases
2023
Centers for Disease Control and Prevention
2012-2023
Kaiser Permanente Washington Health Research Institute
2023
Kaiser Permanente
2023
Texas A&M University
2023
Since SARS-CoV-2, the novel coronavirus that causes disease 2019 (COVID-19), was first detected in December (1), approximately 1.3 million cases have been reported worldwide (2), including 330,000 United States (3). To conduct population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations States, COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) created using existing infrastructure of Influenza (FluSurv-NET) (4) and Respiratory Syncytial Virus...
As compared with a standard-dose vaccine, high-dose, trivalent, inactivated influenza vaccine (IIV3-HD) improves antibody responses to among adults 65 years of age or older. This study evaluated whether IIV3-HD also protection against laboratory-confirmed illness.We conducted phase IIIb-IV, multicenter, randomized, double-blind, active-controlled trial compare (60 μg hemagglutinin per strain) (IIV3-SD [15 strain]) in Assessments relative efficacy, effectiveness, safety (serious adverse...
Abstract Background Currently, the United States has largest number of reported coronavirus disease 2019 (COVID-19) cases and deaths globally. Using a geographically diverse surveillance network, we describe risk factors for severe outcomes among adults hospitalized with COVID-19. Methods We analyzed data from 2491 laboratory-confirmed COVID-19 between 1 March–2 May 2020, as identified through Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, which comprises 154...
A comprehensive understanding of the benefits COVID-19 vaccination requires consideration disease attenuation, determined as whether people who develop despite have lower severity than unvaccinated people.
To characterize the clinical severity of covid-19 associated with alpha, delta, and omicron SARS-CoV-2 variants among adults admitted to hospital compare effectiveness mRNA vaccines prevent admissions related each variant.
In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for Pfizer-BioNTech COVID-19 (BNT162b2) vaccine Moderna (mRNA-1273) vaccine,† Advisory Committee on Immunization Practices (ACIP) interim recommendations their use in persons aged ≥16 years ≥18 years, respectively.§ May 2021, FDA expanded EUA to include adolescents 12-15 years; ACIP recommends that all ≥12 receive a vaccine. Both vaccines are mRNA encoding stabilized prefusion spike...
This report describes the interim recommendation made by Advisory Committee on Immunization Practices December 12, 2020, for use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years.
COVID-NET conducts population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations in 99 counties † 14 states (California, Connecticut, Colorado, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, York, Ohio, Oregon, Tennessee, and Utah), representing all 10 U.S. Department of Health Human Services regions (2,3).Laboratory-confirmed COVID-19associated among residents a predefined catchment area who had positive SARS-CoV-2 molecular test during...
Data are not complete for all characteristics in the table; denominators
The first vaccines for prevention of coronavirus disease 2019 (COVID-19) in the United States were authorized emergency use by Food and Drug Administration (FDA) (1) recommended Advisory Committee on Immunization Practices (ACIP) December 2020.* However, demand COVID-19 is expected to exceed supply during months national vaccination program. ACIP advises CDC population groups circumstances vaccine use.† On 1, that 1) health care personnel§ 2) residents long-term facilities¶ be offered first,...
Pregnant women might be at increased risk for severe coronavirus disease 2019 (COVID-19) (1,2). The COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) (3) collects data on hospitalized pregnant with laboratory-confirmed SARS-CoV-2, the virus that causes COVID-19; to date, such have been limited. During March 1-August 22, 2020, approximately one in four aged 15-49 years COVID-19 was pregnant. Among 598 COVID-19, 54.5% were asymptomatic admission. 272 who symptomatic hospital...
The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic disrupted all sectors society. Less than 1 year after SARS-CoV-2 genome was first sequenced, an application* for Emergency Use Authorization candidate vaccine been filed with Food and Drug Administration (FDA). However, even if one or more candidates receive authorization emergency use, demand COVID-19 is expected exceed supply during months national vaccination program....
Abstract Background Data on risk factors for coronavirus disease 2019 (COVID-19)–associated hospitalization are needed to guide prevention efforts and clinical care. We sought identify independently associated with COVID-19–associated hospitalizations. Methods Community-dwelling adults (aged ≥18 years) in the United States hospitalized laboratory-confirmed COVID-19 during 1 March–23 June 2020 were identified from COVID-19–Associated Hospitalization Surveillance Network (COVID-NET), a...
On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Moderna COVID-19 (mRNA-1273) vaccine (ModernaTX, Inc; Cambridge, Massachusetts), a lipid nanoparticle-encapsulated, nucleoside-modified mRNA encoding stabilized prefusion spike glycoprotein of SARS-CoV-2, virus that causes coronavirus disease 2019 (COVID-19) (1). This is second authorized under EUA prevention in United States (2). Vaccination with consists 2 doses (100 μg, 0.5 mL...
Background. We performed a prospective study to determine the disease burden of respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) in older adults comparison with influenza virus.
This report updates the 2020-21 recommendations of Advisory Committee on Immunization Practices (ACIP) regarding use seasonal influenza vaccines in United States (MMWR Recomm Rep 2020;69[No. RR-8]). Routine annual vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. ACIP makes no preferential recommendation specific when more than one licensed, recommended, available. During...
Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first vaccines approved use under an Emergency Use Authorization (EUA) in United States (1-3). In evaluation 24 hospitals 14 states,* effectiveness of partial or full vaccination† with Pfizer-BioNTech Moderna against COVID-19-associated hospitalization was assessed among adults years. Among 417 hospitalized (including 187 case-patients 230 controls), median age...
In 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food Drug Administration for adults aged ≥18 years, based on studies that compared antibody responses to PCV20 PCV15 with those 13-valent (PCV13) Inc.). Antibody two additional serotypes included in corresponding after PCV13 vaccination, seven 23-valent polysaccharide (PPSV23) Corp.). On October 20,...
hospital admissions are subject to lag.
Abstract Background The severity of the 2017–2018 influenza season in United States was high, with A(H3N2) viruses predominating. Here, we report vaccine effectiveness (VE) and estimate number vaccine-prevented influenza-associated illnesses, medical visits, hospitalizations, deaths for season. Methods We used national age-specific estimates coverage disease burden. estimated VE against medically attended reverse-transcription polymerase chain reaction–confirmed virus infection ambulatory...
Improved understanding of transmission SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), within households could aid control measures. However, few studies have systematically characterized SARS-CoV-2 in U.S. (1). Previously reported rates vary widely, and data on from children are limited. To assess household transmission, a case-ascertained study was conducted Nashville, Tennessee, Marshfield, Wisconsin, commencing April 2020. In this study, index patients were defined...
Background. Influenza vaccines may be reformulated annually because of antigenic drift in influenza viruses. However, the relationship between characteristics circulating viruses and vaccine effectiveness (VE) is not well understood. We conducted an assessment US during 2010–2011 season. Methods. performed a case–control study comparing vaccination histories subjects with acute respiratory illness positive real-time reverse transcription polymerase chain reaction for test-negative controls....
This report updates the 2021-22 recommendations of Advisory Committee on Immunization Practices (ACIP) concerning use seasonal influenza vaccines in United States (MMWR Recomm Rep 2021;70[No.RR-5]:1-24).Routine annual vaccination is recommended for all persons aged ≥6 months who do not have contraindications.For each recipient, a licensed and age-appropriate vaccine should be used.With exception adults ≥65 years, ACIP makes no preferential recommendation specific when more than one licensed,...
OBJECTIVES Describe population-based rates and risk factors for pediatric severe coronavirus disease 2019 (COVID-19) (ie, ICU admission, invasive mechanical ventilation, or death). METHODS During March 2020 to May 2021, the COVID-19–Associated Hospitalization Surveillance Network identified 3106 children hospitalized with laboratory-confirmed acute respiratory syndrome 2 infection in 14 states. Among 2293 primarily admitted COVID-19, multivariable generalized estimating equations generated...
Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability protection. In an evaluation at 21 hospitals in 18 states, the duration mRNA vaccine (Pfizer-BioNTech or Moderna) (VE) was assessed among adults aged ≥18 years. Among 3,089 hospitalized (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), median age 59 years,...